S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:KPTI

Karyopharm Therapeutics (KPTI) Stock Forecast, Price & News

$1.37
0.00 (0.00%)
(As of 09/28/2023 ET)
Compare
Today's Range
$1.25
▼
$1.38
50-Day Range
$1.14
▼
$1.81
52-Week Range
$1.11
▼
$6.01
Volume
1.03 million shs
Average Volume
2.64 million shs
Market Capitalization
$156.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.67
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Karyopharm Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
386.6% Upside
$6.67 Price Target
Short Interest
Bearish
13.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.11mentions of Karyopharm Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$50,191 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.10) to ($0.90) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

505th out of 969 stocks

Pharmaceutical Preparations Industry

234th out of 455 stocks

See Top Rated MarketRank™ Stocks Here

KPTI stock logo

About Karyopharm Therapeutics (NASDAQ:KPTI) Stock

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

KPTI Price History

KPTI Stock News Headlines

September 26, 2023 | finance.yahoo.com
Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings
September 1, 2023 | finance.yahoo.com
Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors
September 28, 2023 | The Oxford Club (Ad)
Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
August 21, 2023 | msn.com
Karyopharm Therapeutics: Seeking Upside Potential But Catalysts Too Far Away
August 4, 2023 | msn.com
Piper Sandler Maintains Karyopharm Therapeutics (KPTI) Overweight Recommendation
August 3, 2023 | benzinga.com
6 Analysts Have This to Say About Karyopharm Therapeutics
August 3, 2023 | finance.yahoo.com
Dozens more biotech jobs axed as two firms make cuts
August 3, 2023 | markets.businessinsider.com
Karyopharm Therapeutics (KPTI) Gets a Buy from Barclays
September 28, 2023 | The Oxford Club (Ad)
Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
August 3, 2023 | finance.yahoo.com
Karyopharm Therapeutics (KPTI) Q2 2023 Earnings Call Transcript
August 2, 2023 | markets.businessinsider.com
Karyopharm Therapeutics Inc. Q2 Loss decreases, beats estimates
August 2, 2023 | finance.yahoo.com
Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
July 27, 2023 | markets.businessinsider.com
Analysts Conflicted on These Healthcare Names: Gossamer Bio (GOSS), Karyopharm Therapeutics (KPTI) and Tarsus Pharmaceuticals (TARS)
July 27, 2023 | markets.businessinsider.com
H.C. Wainwright Reaffirms Their Buy Rating on Karyopharm Therapeutics (KPTI)
July 27, 2023 | msn.com
Wedbush Maintains Karyopharm Therapeutics (KPTI) Neutral Recommendation
July 27, 2023 | finance.yahoo.com
Karyopharm Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer
July 27, 2023 | finance.yahoo.com
Karyopharm to Report Second Quarter 2023 Financial Results on August 2, 2023
July 19, 2023 | finance.yahoo.com
Karyopharm Announces Updated Exploratory Subgroup Analysis from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer to be Presented at ASCO Plenary Series on July 25th
July 18, 2023 | theglobeandmail.com
Healthcare Stock Bid Up Following FDA Fast Track
July 18, 2023 | markets.businessinsider.com
4 Analysts Have This to Say About Karyopharm Therapeutics
July 17, 2023 | finance.yahoo.com
Karyopharm Receives FDA Fast Track Designation for Selinexor for the Treatment of Myelofibrosis
July 10, 2023 | markets.businessinsider.com
RBC Capital Reaffirms Their Buy Rating on Karyopharm Therapeutics (KPTI)
July 5, 2023 | finance.yahoo.com
All You Need to Know About Karyopharm Therapeutics (KPTI) Rating Upgrade to Buy
June 28, 2023 | finance.yahoo.com
Karyopharm Initiates Pivotal Phase 3 Study of XPO1 Inhibitor Selinexor and Ruxolitinib in JAK Inhibitor (JAKi) Naïve Myelofibrosis
June 8, 2023 | finance.yahoo.com
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is favoured by institutional owners who hold 74% of the company
June 7, 2023 | markets.businessinsider.com
SVB Securities Sticks to Their Hold Rating for Karyopharm Therapeutics (KPTI)
May 29, 2023 | markets.businessinsider.com
SVB Securities Remains a Hold on Karyopharm Therapeutics (KPTI)
See More Headlines
Receive KPTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KPTI Company Calendar

Last Earnings
8/02/2023
Today
9/28/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KPTI
CUSIP
N/A
CIK
1503802
Web
www.karyopharm.com
Phone
(617) 658-0600
Fax
N/A
Employees
385
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.67
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+393.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-165,290,000.00
Net Margins
-96.97%
Pretax Margin
-96.77%
Return on Equity
N/A
Return on Assets
-46.69%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.94
Quick Ratio
4.88

Sales & Book Value

Annual Sales
$157.07 million
Price / Sales
0.98
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.15) per share
Price / Book
-9.00

Miscellaneous

Outstanding Shares
114,360,000
Free Float
110,558,000
Market Cap
$154.39 million
Optionable
Optionable
Beta
-0.01
10 Best Stocks to Own in 2023 Cover
10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Richard A. Paulson M.B.A. (Age 56)
    Pres, CEO & Director
    Comp: $1.36M
  • Dr. Sharon Shacham M.B.A. (Age 53)
    Ph.D., Co-Founder & Chairman of Scientific Advisory Board
    Comp: $1.4M
  • Mr. Michael P. Mason CPAMr. Michael P. Mason CPA (Age 48)
    M.B.A., Exec. VP, CFO & Treasurer
    Comp: $681.59k
  • Mr. Michael J. Mano J.D. (Age 46)
    Sr. VP, Gen. Counsel & Sec.
    Comp: $625.08k
  • Ms. Sohanya Cheng M.B.A. (Age 40)
    Exec. VP & Chief Commercial Officer
    Comp: $664.3k
  • Mr. Stuart Poulton
    Exec. VP & Chief Devel. Officer
  • Dr. Mansoor Raza Mirza M.D. (Age 62)
    Clinical Consultant, Member of Scientific Advisory Board & Independent Director
    Comp: $150k
  • Mr. Cameron Peters (Age 63)
    VP of Fin., Assistant Treasurer & Principal Accounting Officer
  • Ms. Elhan Webb C.F.A.
    Sr. VP of Investor Relations
  • Mr. James Accumanno J.D.
    Chief Compliance Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













KPTI Stock - Frequently Asked Questions

Should I buy or sell Karyopharm Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KPTI shares.
View KPTI analyst ratings or view top-rated stocks.

What is Karyopharm Therapeutics' stock price forecast for 2023?

5 Wall Street analysts have issued 1 year target prices for Karyopharm Therapeutics' stock. Their KPTI share price forecasts range from $4.00 to $10.00. On average, they anticipate the company's share price to reach $6.67 in the next twelve months. This suggests a possible upside of 393.8% from the stock's current price.
View analysts price targets for KPTI or view top-rated stocks among Wall Street analysts.

How have KPTI shares performed in 2023?

Karyopharm Therapeutics' stock was trading at $3.40 at the beginning of 2023. Since then, KPTI stock has decreased by 60.3% and is now trading at $1.35.
View the best growth stocks for 2023 here.

When is Karyopharm Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our KPTI earnings forecast.

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) issued its earnings results on Wednesday, August, 2nd. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.05. The company earned $37.58 million during the quarter, compared to analysts' expectations of $36.23 million.

What ETF holds Karyopharm Therapeutics' stock ?

iShares Genomics Immunology and Healthcare ETF holds 391,728 shares of KPTI stock, representing 0.49% of its portfolio.

What guidance has Karyopharm Therapeutics issued on next quarter's earnings?

Karyopharm Therapeutics updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $145.00 million-$160.00 million, compared to the consensus revenue estimate of $150.34 million.

What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO?

31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Who are Karyopharm Therapeutics' major shareholders?

Karyopharm Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.09%), Marshall Wace LLP (2.14%), ExodusPoint Capital Management LP (2.08%), State Street Corp (1.93%), Geode Capital Management LLC (1.87%) and Goldman Sachs Group Inc. (1.42%). Insiders that own company stock include Christopher Brett Primiano, Deepika Pakianathan, Garen G Bohlin, Jatin Shah, Mansoor Raza Mirza, Michael Kauffman, Michael Mano, Michael Mason, Reshma Rangwala, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener, Stuart Poulton and Tanya Lewis.
View institutional ownership trends.

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Karyopharm Therapeutics' stock price today?

One share of KPTI stock can currently be purchased for approximately $1.35.

How much money does Karyopharm Therapeutics make?

Karyopharm Therapeutics (NASDAQ:KPTI) has a market capitalization of $154.39 million and generates $157.07 million in revenue each year. The company earns $-165,290,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis.

How many employees does Karyopharm Therapeutics have?

The company employs 385 workers across the globe.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The official website for the company is www.karyopharm.com. The company can be reached via phone at (617) 658-0600 or via email at ikarp@karyopharm.com.

This page (NASDAQ:KPTI) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -